Home / Episodes / Tue, Nov 17, 2026

J&J to Buy Ollin for $2.2B Upfront & Roche’s Wilserdly Combo Approved for Breast Cancer

Tue, Nov 17, 2026 15 min Hosts: Alex Mercer & Maya Patel
▶ Listen

In this delayed Monday closeout, Johnson & Johnson agreed to buy Ollin Biosciences for $2.2 billion upfront, and Blackstone agreed to fund Phase 3 work on OLN324 in wet AMD and diabetic macular edema if the acquisition closes. The FDA approved Roche's Wilserdly (giredestrant) with everolimus for ESR1-mutated advanced breast cancer after endocrine therapy. In the daily roundup: CG Oncology's cretostimogene bladder cancer data, Servier's Ojemda (tovorafenib) follow-up in pediatric low-grade glioma, Lilly's Calytrix Bio deal, AstraZeneca's Klygefa (gefurulimab) approval in myasthenia gravis, Novo Nordisk's semaglutide data in children, and AriBio's split AR1001 Alzheimer's result.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

Close out your day

The whole read, every morning

The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.

Subscribe →